6:34 PM
 | 
Oct 31, 2012
 |  BC Extra  |  Company News

BioMarin grants North American Firdapse rights to Catalyst

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) granted exclusive, North American rights for Orphan drug Firdapse amifampridine to Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX). BioMarin, which is eligible for undisclosed royalties, will invest $5 million in Catalyst to support development of Firdapse in the U.S....

Read the full 197 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >